3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
Vincristine
9
Cyclophosphamide
8
Magnetic Resonance Spectroscopy
7
X-Rays
6
Temozolomide
6
Specimen Handling
6
Phantoms, Imaging
6
Irinotecan
6
Biopsy
5
Radiotherapy
4
Radiation
4
Nuclear Medicine Department, Hospital
4
Dactinomycin
4
fludarabine
3
Vinorelbine
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
ensartinib
2
Proton Therapy
2
LY3023414
2
Ifosfamide
2
Filgrastim
2
Etoposide
2
Doxorubicin
2
Dexrazoxane
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rhabdomyosarcoma
×
amino-acid, glucose, and electrolyte solution
×
90 days
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled